Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alvine Pharmaceuticals said that the US Patent and Trademark Office has granted two key patents covering celiac disease therapies.
Subscribe to our email newsletter
These patents will cover gluten detoxification with proline specific prolyl endopeptidases (PEPs) and with mixtures of a PEP and a glutamine specific protease.
Alvine has an exclusive worldwide license to these patents under an agreement with Stanford University. Both patents provide important protection for ALV003, Alvine’s lead product currently in clinical development for use in the treatment of celiac disease.